RxDoctor Payments Data

John Sullivan, MD

Psychiatry · San Diego, CANPI 1851597389

Payments from drug & device makers

$13,886in general payments, 2019–2025

Across 461 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • plus $3K from 7 others

What the payments were for

  • Consulting fees$3,68027%
  • Food & beverage$9,71170%
  • Education$4954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,886 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$6,908
Medicare patients
26
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$166,695
Austedo XrDeutetrabenazine11$131,436
CaplytaLumateperone Tosylate78$73,995
Abilify AsimtufiiAripiprazole11$59,198
VraylarCariprazine Hcl41$47,747
RexultiBrexpiprazole20$18,152
Asenapine Maleate21$2,731
Olanzapine OdtOlanzapine58$1,924
Fluoxetine DrFluoxetine Hcl34$1,524
Acamprosate Calcium23$1,123
Trazodone Hcl52$530
Aripiprazole76$486
Naltrexone Hcl44$464
AmantadineAmantadine Hcl55$443
Buspirone Hcl19$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$781$166,69527 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,503$131,43611 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti$1,130$77,35031 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,665$73,99578 claims
AbbVieVraylar$862$47,74741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →